220 related articles for article (PubMed ID: 15750626)
21. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
He Z; Liu S; Guo M; Mao J; Hughson MD
Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
[TBL] [Abstract][Full Text] [Related]
22. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP.
Sang N; Fang J; Srinivas V; Leshchinsky I; Caro J
Mol Cell Biol; 2002 May; 22(9):2984-92. PubMed ID: 11940656
[TBL] [Abstract][Full Text] [Related]
23. Decreased growth of Vhl-/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27.
Mack FA; Patel JH; Biju MP; Haase VH; Simon MC
Mol Cell Biol; 2005 Jun; 25(11):4565-78. PubMed ID: 15899860
[TBL] [Abstract][Full Text] [Related]
24. Nitric oxide donor, (+/-)-S-nitroso-N-acetylpenicillamine, stabilizes transactive hypoxia-inducible factor-1alpha by inhibiting von Hippel-Lindau recruitment and asparagine hydroxylation.
Park YK; Ahn DR; Oh M; Lee T; Yang EG; Son M; Park H
Mol Pharmacol; 2008 Jul; 74(1):236-45. PubMed ID: 18426857
[TBL] [Abstract][Full Text] [Related]
25. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
[TBL] [Abstract][Full Text] [Related]
26. Leu-574 of HIF-1alpha is essential for the von Hippel-Lindau (VHL)-mediated degradation pathway.
Huang LE; Pete EA; Schau M; Milligan J; Gu J
J Biol Chem; 2002 Nov; 277(44):41750-5. PubMed ID: 12205091
[TBL] [Abstract][Full Text] [Related]
27. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
[TBL] [Abstract][Full Text] [Related]
28. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein.
Groulx I; Lee S
Mol Cell Biol; 2002 Aug; 22(15):5319-36. PubMed ID: 12101228
[TBL] [Abstract][Full Text] [Related]
29. HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases.
Paltoglou S; Roberts BJ
Oncogene; 2007 Jan; 26(4):604-9. PubMed ID: 16862177
[TBL] [Abstract][Full Text] [Related]
30. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
32. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.
Rankin EB; Higgins DF; Walisser JA; Johnson RS; Bradfield CA; Haase VH
Mol Cell Biol; 2005 Apr; 25(8):3163-72. PubMed ID: 15798202
[TBL] [Abstract][Full Text] [Related]
33. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Beppu K; Nakamura K; Linehan WM; Rapisarda A; Thiele CJ
Cancer Res; 2005 Jun; 65(11):4775-81. PubMed ID: 15930297
[TBL] [Abstract][Full Text] [Related]
34. OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha.
Baek JH; Mahon PC; Oh J; Kelly B; Krishnamachary B; Pearson M; Chan DA; Giaccia AJ; Semenza GL
Mol Cell; 2005 Feb; 17(4):503-12. PubMed ID: 15721254
[TBL] [Abstract][Full Text] [Related]
35. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L
Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486
[TBL] [Abstract][Full Text] [Related]
36. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.
Li Z; Wang D; Na X; Schoen SR; Messing EM; Wu G
EMBO J; 2003 Apr; 22(8):1857-67. PubMed ID: 12682018
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation.
Jung Y; Isaacs JS; Lee S; Trepel J; Liu ZG; Neckers L
Biochem J; 2003 Mar; 370(Pt 3):1011-7. PubMed ID: 12479793
[TBL] [Abstract][Full Text] [Related]
38. Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein.
Lewis MD; Roberts BJ
Oncogene; 2003 Jun; 22(26):3992-7. PubMed ID: 12821933
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
40. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]